U.S. markets open in 4 hours 5 minutes
  • S&P Futures

    4,254.75
    -31.75 (-0.74%)
     
  • Dow Futures

    33,792.00
    -189.00 (-0.56%)
     
  • Nasdaq Futures

    13,400.50
    -122.75 (-0.91%)
     
  • Russell 2000 Futures

    1,983.60
    -18.10 (-0.90%)
     
  • Crude Oil

    89.43
    -1.07 (-1.18%)
     
  • Gold

    1,766.20
    -5.00 (-0.28%)
     
  • Silver

    19.11
    -0.35 (-1.82%)
     
  • EUR/USD

    1.0085
    -0.0007 (-0.07%)
     
  • 10-Yr Bond

    2.8800
    0.0000 (0.00%)
     
  • Vix

    20.61
    +0.71 (+3.57%)
     
  • GBP/USD

    1.1875
    -0.0058 (-0.49%)
     
  • USD/JPY

    136.5390
    +0.6770 (+0.50%)
     
  • BTC-USD

    21,718.54
    -1,733.68 (-7.39%)
     
  • CMC Crypto 200

    516.17
    -41.57 (-7.45%)
     
  • FTSE 100

    7,525.97
    -15.88 (-0.21%)
     
  • Nikkei 225

    28,930.33
    -11.81 (-0.04%)
     

Prothena (PRTA) IND Application Gets FDA Clearance for AD

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Prothena Corporation plc PRTA announced that the FDA has cleared the investigational new drug (IND) application for pipeline candidate PRX012 for the treatment of Alzheimer’s disease (AD).

PRX012 is a potential best-in-class anti-amyloid beta (Aβ) antibody. Prothena has initiated the phase I single ascending dose (SAD) study to evaluate the safety, tolerability, immunogenicity and pharmacokinetics of PRX012 in both healthy volunteers and patients with AD.

In this phase I SAD study, healthy volunteers and patients will be randomized to receive a single subcutaneous injection of either PRX012 or placebo.

Prothena expects to initiate the phase I multiple ascending dose study by year-end 2022.

Data from preclinical studies showed that PRX012 binds to beta amyloid plaques and oligomers with high avidity, enabling effective levels of Aβ plaque occupancy at relatively lower dose ranges, which are optimal for subcutaneous delivery.

The company’s shares have declined 25.2% in the year so far compared with the industry’s fall of 13.2%.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

The FDA approval of Biogen’s BIIB AD drug, Aduhelm, in June 2021 has put the spotlight on companies with promising AD candidates in their pipeline. Prothena is one of the frontrunners.

Prothena is advancing an early-stage pipeline of programs for a number of potential neurological indications with Bristol Myers BMY. This includes PRX005 — a potential treatment for AD — is an investigational antibody that targets tau, a protein implicated in diseases including AD, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy and other tauopathies. The company has received an $80 million option payment from Bristol Myers to execute the U.S. license agreement in 2021. A phase I study was initiated in 2021, and top-line data is expected in 2022.

The company is also developing a dual Aβ-Tau vaccine — a potential prevention and treatment for AD — to target key epitopes within Aβ and tau proteins for promoting amyloid clearance as well as blockade pathogenic tau interaction. An IND for the vaccine is anticipated in 2023.

However, the uptake of Biogen’s Aduhelm has been slow due to limited patient access amid a lack of clarity on Aduhelm reimbursement.

Hence, there is a long way to go for companies like Prothena in the AD space.

Prothena currently carries a Zacks Rank #4 (Sell).

A better-ranked stock in the biotech sector is Vertex Pharmaceuticals VRTX which currently carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The consensus estimate for Vertex’s 2022 earnings has increased $1.13 over the past 60 days to $14.52. Shares of VRTX have gained 16.4% in the past year.



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Biogen Inc. (BIIB) : Free Stock Analysis Report

Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report

Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report

Prothena Corporation plc (PRTA) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research